Elahere Global Market Opportunities And Strategies To 2034

Description

Elahere (mirvetuximab soravtansine-gynx) is a prescription medication designed for the treatment of adult patients with folate receptor-alpha (FRa) positive ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. It is specifically indicated for individuals who have not responded to or are no longer responding to platinum-based chemotherapy and have received one to three prior types of chemotherapy. Elahere functions as an antibody-drug conjugate (ADC), delivering a cytotoxic agent directly to FRa-positive cancer cells, thereby minimizing damage to healthy tissues.

The elahere market consists of sales, by entities (organizations, sole traders or partnerships), of elahere (mirvetuximab soravtansine-gynx), a targeted antibody-drug conjugate (ADC) specifically designed for treating platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers that express high levels of folate receptor-alpha (FRa).

The global elahere market accounted to $502.56 million in 2024. The growth in the historic period can be attributed to technological advancements and increase in demand for personalized medicine.

Rising Healthcare Expenditure

The rising healthcare expenditure supported the expansion of the elahere market during this historic period. Healthcare expenditure refers to spending on healthcare costs and represents the total amount of money spent on healthcare-related goods and services within a given healthcare system or economy. Increased financial resources in the healthcare sector enable greater investment in innovative treatments, research and development. This funding helps cover the high costs associated with clinical trials, regulatory approvals and the scaling of production for cutting-edge therapies like Elahere. For instance, in 2023, according to the Canadian Institute for Health Information, a US-based not-for-profit organization, Canada's total health spending was estimated to reach $344 billion, or $8,740 per person. The growth in physician spending was estimated to be 6.9% in 2023 and 9.5% in 2022. Therefore, rising healthcare expenditure drove the growth of the elahere market.

Abbvie Secures European Approval For Elahere In Platinum-Resistant Ovarian Cancer

Companies in the elahere market are focusing on obtaining regulatory approvals to expand the treatment's availability for patients with platinum-resistant ovarian cancer. This move aims to strengthen its position in the market by offering a targeted therapy for a specific patient group in need of advanced treatment options. For instance, in November 2024, AbbVie, a US-based biotech company received approval from the European Commission for elahere as a treatment for adult patients with folate receptor-alpha (FR alpha) positive, platinum-resistant ovarian cancer. The approval was based on the positive results from the Phase III MIRASOL trial, which demonstrated a 35% reduction in the risk of disease progression or death compared to standard chemotherapy.

The global elahere market is highly concentrated, with only one player in the market. The top competitor in the market made up 100.0% of the total market in 2023.

Elahere Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global elahere market as it emerges from the COVID-19 shut down.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for elahere? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The elahere market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider elahere market; and compares it with other markets.

The report covers the following chapters

Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by clinical indication, by distribution channel and by end-users.
Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
Growth Analysis And Strategic Analysis Framework Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
Regional And Country Analysis- Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
Market Segmentation- Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by clinical indication, by distribution channel and by end-users in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
Regional Market Size and Growth- Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
Conclusions And Recommendations- This section includes recommendations for elahere providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

1) By Clinical Indication: Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End-User: Hospitals; Specialty Centers; Other End-Users
Companies Mentioned: AbbVie Inc. (ImmunoGen)
Countries: China; Australia; India; Japan; South Korea; USA; Canada; France; Germany; UK
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time-series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; elahere indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Product Code: o&s1535

1 Executive Summary

1.1 Elahere - Market Attractiveness And Macro economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

6.1 General Market Definition
6.2 Summary
6.3 Elahere Market Definition And Segmentations
6.4 Market Segmentation By Clinical Indication
- 6.4.1 Ovarian Neoplasms
- 6.4.2 Fallopian Tube Neoplasms
- 6.4.3 Peritoneal Neoplasms
6.5 Market Segmentation By Distribution Channel
- 6.5.1 Hospital Pharmacies
- 6.5.2 Retail Pharmacies
- 6.5.3 Online Pharmacies
6.6 Market Segmentation By End-Users
- 6.6.1 Hospitals
- 6.6.2 Specialty Centers
- 6.6.3 Other End-Users

7 Elahere Market Biologic Drug Characteristics

7.1 Molecule Type
7.2 Route Of Administration (ROA)
7.3 Mechanism Of Action (MOA)
7.4 Safety And Efficacy

8 Major Market Trends

8.1 Abbvie Secures European Approval For Elahere In Platinum-Resistant Ovarian Cancer
8.2 Strategic Collaboration Targets For Advanced Ovarian Cancer Treatment
8.3 Advanced Diagnostic Tool Aims to Enhance Ovarian Cancer Treatment

9 Global Elahere Growth Analysis And Strategic Analysis Framework

9.1 Global Elahere PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors)
- 9.1.1 Political
- 9.1.2 Economic
- 9.1.3 Social
- 9.1.4 Technological
- 9.1.5 Environmental
- 9.1.6 Legal

10 Analysis Of End Users For B2B Markets

10.1 End Users
- 10.1.1 Hospitals
- 10.1.2 Specialty Centers
- 10.1.3 Other End Users
10.2 Global Market Size and Growth
10.3 Market Size
10.4 Historic Market Growth, 2019 - 2024, Value ($ Million)
- 10.4.1 Market Drivers 2019 - 2024
- 10.4.2 Market Restraints 2019 - 2024
10.5 Forecast Market Growth, 2024 - 2029, 2034F Value ($ Million)
- 10.5.1 Market Drivers 2024 - 2029
- 10.5.2 Market Restraints 2024 - 2029
10.6 Global Elahere Total Addressable Market (TAM)

11 Global Elahere Pricing Analysis & Forecasts

12 Global Elahere Market Segmentation

12.1 Global Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.2 Global Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
12.3 Global Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

13 Global Elahere Epidemiology Of Clinical Indications

13.1 Incidence And Prevalence of Clinical Indications

14 Elahere Market, Regional and Country Analysis

14.1 Global Elahere Market, By Region, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
14.2 Global Elahere Market, By Country, Historic and Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

15 Asia-Pacific Market

15.1 Market Overview
- 15.1.1 Region Information
- 15.1.2 Background Information
- 15.1.3 Government Initiatives
- 15.1.4 Regulations
- 15.1.5 Regulatory Bodies
- 15.1.6 Major Associations
- 15.1.7 Taxes Levied
- 15.1.8 Corporate Tax Structure
- 15.1.9 Investments
15.2 Asia-Pacific Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.3 Asia-Pacific Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.4 Asia-Pacific Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.5 Asia-Pacific Elahere Market: Country Analysis
15.6 China Market
15.7 Market Overview
- 15.7.1 Country Information
- 15.7.2 Background Information
- 15.7.3 Government Initiatives
- 15.7.4 Regulations
- 15.7.5 Regulatory Bodies
- 15.7.6 Major Associations
- 15.7.7 Taxes Levied
- 15.7.8 Corporate Tax Structure
- 15.7.9 Investments
15.8 China Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.9 China Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.10 China Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.11 India Market
15.12 India Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.13 India Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.14 India Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.15 Japan Market
15.16 Market Overview
- 15.16.1 Country Information
- 15.16.2 Background Information
- 15.16.3 Regulations
- 15.16.4 Regulatory Bodies
- 15.16.5 Major Associations
- 15.16.6 Taxes Levied
- 15.16.7 Corporate Tax Structure
- 15.16.8 Investments
15.17 Japan Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.18 Japan Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.19 Japan Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.20 Australia Market
15.21 Australia Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.22 Australia Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.23 Australia Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.24 South Korea Market
15.25 Market Overview
- 15.25.1 Country Information
- 15.25.2 Background Information
- 15.25.3 Government Initiatives
- 15.25.4 Regulations
- 15.25.5 Regulatory Bodies
- 15.25.6 Major Associations
- 15.25.7 Taxes Levied
- 15.25.8 Corporate Tax Structure
15.26 South Korea Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.27 South Korea Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
15.28 South Korea Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

16 Western Europe Market

16.1 Summary
16.2 Market Overview
- 16.2.1 Region Information
- 16.2.2 Market Information
- 16.2.3 Background Information
- 16.2.4 Government Initiatives
- 16.2.5 Regulations
- 16.2.6 Regulatory Bodies
- 16.2.7 Major Associations
- 16.2.8 Taxes Levied
- 16.2.9 Corporate tax structure
- 16.2.10 Investments
16.3 Western Europe Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.4 Western Europe Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.5 Western Europe Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.6 Western Europe Elahere Market: Country Analysis
16.7 UK Market
16.8 UK Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.9 UK Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.10 UK Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.11 Germany Market
16.12 Germany Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.13 Germany Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.14 Germany Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.15 France Market
16.16 France Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.17 France Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
16.18 France Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

17 Eastern Europe Market

17.1 Summary
17.2 Market Overview
- 17.2.1 Region Information
- 17.2.2 Market Information
- 17.2.3 Background Information
- 17.2.4 Government Initiatives
- 17.2.5 Regulations
- 17.2.6 Regulatory Bodies
- 17.2.7 Major Association
- 17.2.8 Taxes Levied
- 17.2.9 Corporate Tax Structure
17.3 Eastern Europe Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17.4 Eastern Europe Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
17.5 Eastern Europe Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

18 North America Market

18.1 Summary
18.2 Market Overview
- 18.2.1 Region Information
- 18.2.2 Market Information
- 18.2.3 Background Information
- 18.2.4 Government Initiatives
- 18.2.5 Regulations
- 18.2.6 Regulatory Bodies
- 18.2.7 Major Associations
- 18.2.8 Taxes Levied
- 18.2.9 Corporate Tax Structure
- 18.2.10 Investments
18.3 North America Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
18.4 North America Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
18.5 North America Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
18.6 North America Elahere Market: Country Analysis
18.7 USA Market
18.8 Summary
18.9 Market Overview
- 18.9.1 Country Information
- 18.9.2 Market Information
- 18.9.3 Background Information
- 18.9.4 Government Initiatives
- 18.9.5 Regulations
- 18.9.6 Regulatory Bodies
- 18.9.7 Major Associations
- 18.9.8 Taxes Levied
- 18.9.9 Corporate Tax Structure
- 18.9.10 Investments
18.1 USA Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
18.11 USA Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
18.12 USA Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
18.13 Canada Market
18.14 Market Overview
- 18.14.1 Country Information
- 18.14.2 Background Information
- 18.14.3 Government Initiatives
- 18.14.4 Regulations
- 18.14.5 Regulatory Bodies
- 18.14.6 Major Associations
- 18.14.7 Taxes Levied
- 18.14.8 Corporate Tax Structure
18.15 Canada Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
18.16 Canada Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
18.17 Canada Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

19 South America Market

19.1 Market Overview
- 19.1.1 Region Information
- 19.1.2 Background Information
- 19.1.3 Government Initiatives
- 19.1.4 Regulations
- 19.1.5 Regulatory Bodies
- 19.1.6 Major Associations
- 19.1.7 Taxes Levied
- 19.1.8 Corporate Tax Structure
19.2 South America Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
19.3 South America Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
19.4 South America Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

20 Middle East Market

20.1 Market Overview
- 20.1.1 Region Information
- 20.1.2 Market Information
- 20.1.3 Background Information
- 20.1.4 Government Initiatives
- 20.1.5 Regulations
- 20.1.6 Regulatory Bodies
- 20.1.7 Major Associations
- 20.1.8 Taxes Levied
- 20.1.9 Corporate Tax Structure
20.2 Middle East Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
20.3 Middle East Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
20.4 Middle East Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

21 Africa Market

21.1 Market Overview
- 21.1.1 Region Information
- 21.1.2 Background Information
- 21.1.3 Government Initiatives
- 21.1.4 Regulations
- 21.1.5 Regulatory Bodies
- 21.1.6 Major Associations
- 21.1.7 Taxes Levied
- 21.1.8 Corporate Tax Structure
21.2 Africa Elahere Market, Segmentation By Clinical Indication, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
21.3 Africa Elahere Market, Segmentation By Distribution Channel, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)
21.4 Africa Elahere Market, Segmentation By End-Users, Historic And Forecast, 2019 - 2024, 2029F, 2034F, Value ($ Million)

22 Competitive Landscape And Company Profiles

22.1 Company Profiles
22.2 AbbVie Inc. (ImmunoGen)
- 22.2.1 Company Overview
- 22.2.2 Products And Services
- 22.2.3 Business Strategy
- 22.2.4 Financial Overview

23 Global Elahere Market Pipeline Analysis

24 Key Mergers And Acquisitions

24.1 AbbVie Acquired ImmunoGen

25 Opportunities And Strategies

25.1 Global Elahere Market In 2029 - Countries Offering Most New Opportunities
25.2 Global Elahere Market In 2029 - Segments Offering Most New Opportunities
25.3 Global Elahere Market In 2029 - Growth Strategies
- 25.3.1 Market Trend Based Strategies
- 25.3.2 Competitor Strategies

26 Elahere Market, Conclusions And Recommendations

26.1 Conclusions
26.2 Recommendations
- 26.2.1 Product
- 26.2.2 Place
- 26.2.3 Price
- 26.2.4 Promotion
- 26.2.5 People

27 Appendix

27.1 Geographies Covered
27.2 Market Data Sources
27.3 Research Methodology
27.4 Currencies
27.5 The Business Research Company
27.6 Copyright and Disclaimer